Covered recipient · General Payments record
ROBERT J BUYNAK
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$2,547.31
21 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,577.83 | 6 |
| Food and Beverage | $969.48 | 15 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim International GmbH | $1,595.00 | 13 |
| Alnylam Pharmaceuticals Inc. | $952.31 | 8 |
Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBERT J BUYNAK
NPI 1508977984 · CMS profile ID 340544
Allopathic & Osteopathic Physicians / Internal Medicine
VALPARAISO, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508977984?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508977984?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508977984?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1508977984?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
21 matching records · $2,547.31 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–21 of 21.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim International GmbH | $50.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331053 | CMS |
| Boehringer Ingelheim International GmbH | $40.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331055 | CMS |
| Boehringer Ingelheim International GmbH | $258.23 | 10/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331057 | CMS |
| Boehringer Ingelheim International GmbH | $117.11 | 10/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331059 | CMS |
| Boehringer Ingelheim International GmbH | $40.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331061 | CMS |
| Boehringer Ingelheim International GmbH | $145.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331063 | CMS |
| Boehringer Ingelheim International GmbH | $40.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331065 | CMS |
| Boehringer Ingelheim International GmbH | $50.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331067 | CMS |
| Boehringer Ingelheim International GmbH | $145.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331069 | CMS |
| Boehringer Ingelheim International GmbH | $50.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331071 | CMS |
| Boehringer Ingelheim International GmbH | $50.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017333561 | CMS |
| Boehringer Ingelheim International GmbH | $258.23 | 10/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017333567 | CMS |
| Boehringer Ingelheim International GmbH | $351.43 | 08/30/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017332783 | CMS |
| Alnylam Pharmaceuticals Inc. | $270.10 | 01/26/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006151427 | CMS |
| Alnylam Pharmaceuticals Inc. | $89.99 | 01/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006151433 | CMS |
| Alnylam Pharmaceuticals Inc. | $71.30 | 01/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006151439 | CMS |
| Alnylam Pharmaceuticals Inc. | $49.83 | 01/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006151443 | CMS |
| Alnylam Pharmaceuticals Inc. | $44.99 | 01/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006151449 | CMS |
| Alnylam Pharmaceuticals Inc. | $60.81 | 01/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006151453 | CMS |
| Alnylam Pharmaceuticals Inc. | $42.56 | 01/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006151461 | CMS |
| Alnylam Pharmaceuticals Inc. | $322.73 | 01/26/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006151465 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,038,550.53 | 603 |
| PY2024 | Principal investigator | $5,031,915.33 | 601 |
| PY2023 | Recipient | $906.71 | 2 |
| PY2023 | Principal investigator | $4,138,599.32 | 2,384 |
| PY2022 | Recipient | $3,104.59 | 10 |
| PY2022 | Principal investigator | $5,204,363.35 | 1,133 |
| PY2021 | Principal investigator | $3,348,948.64 | 610 |
| PY2020 | Recipient | $1,489.26 | 13 |
| PY2020 | Principal investigator | $1,938,354.41 | 292 |
| PY2019 | Recipient | $658.79 | 10 |
| PY2019 | Principal investigator | $1,439,149.33 | 218 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
1,143 records in PY2022
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $954.74 | 12/31/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) | No dispute reported | 06/30/2026 | 914602811 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115969 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115971 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115973 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115975 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115977 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115979 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115981 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115983 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115985 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116095 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116097 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116099 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116101 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116103 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116105 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116107 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116109 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116111 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116113 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116115 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116117 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116119 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116121 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116123 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116125 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116127 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116129 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 12/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116131 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $8,429.00 | 12/27/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218333 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $12,000.00 | 12/27/2022 | Non-covered Recipient Entity Velocity Clinical Research,Inc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 935555551 |
| Principal investigator 1 | ModernaTX, Inc. | $84,367.60 | 12/23/2022 | Non-covered Recipient Entity Velocity Clinical Research, Spartanburg | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963687579 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 12/23/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897268125 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $64,754.39 | 12/23/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 935559689 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,190.00 | 12/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116367 |
| Principal investigator 1 | Novo Nordisk AS | $1,947.95 | 12/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854533 |
| Principal investigator 1 | Novo Nordisk AS | $432.00 | 12/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897162839 |
| Principal investigator 1 | PFIZER INC. | $810.00 | 12/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949772293 |
| Principal investigator 1 | PFIZER INC. | $33,736.50 | 12/17/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949772257 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,603.79 | 12/16/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO | No dispute reported | 06/30/2026 | 943949435 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $21,619.00 | 12/16/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218345 |
| Principal investigator 1 | ModernaTX, Inc. | $15,633.68 | 12/16/2022 | Non-covered Recipient Entity Velocity Clinical Research, Spartanburg | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963687115 |
| Principal investigator 1 | ModernaTX, Inc. | $156,589.60 | 12/16/2022 | Non-covered Recipient Entity Velocity Clinical Research, Spartanburg | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963687559 |
| Principal investigator 1 | ModernaTX, Inc. | $13,448.40 | 12/16/2022 | Non-covered Recipient Entity Velocity Clinical Research, Spartanburg | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963687561 |
| Principal investigator 1 | PFIZER INC. | $23,814.00 | 12/16/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949772087 |
| Principal investigator 1 | PFIZER INC. | $43,861.50 | 12/10/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949772253 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $3,983.00 | 12/05/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218337 |
| Principal investigator 1 | PFIZER INC. | $5,953.50 | 12/03/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949772255 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $4,317.00 | 12/02/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116363 |
| Principal investigator 1 | ModernaTX, Inc. | $14,562.79 | 12/02/2022 | Non-covered Recipient Entity Velocity Clinical Research, Spartanburg | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963687099 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 12/02/2022 | Non-covered Recipient Entity Velocity Clinical Research, Spartanburg | Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study | No dispute reported | 06/30/2026 | 963687679 |
| Principal investigator 1 | Novo Nordisk AS | $2,567.27 | 12/02/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896939067 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 12/01/2022 | Non-covered Recipient Entity Velocity Clinical Research, Spartanburg | Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study | No dispute reported | 06/30/2026 | 963687665 |
| Principal investigator 1 | PFIZER INC. | $37.26 | 12/01/2022 | Non-covered Recipient Entity Velocity Clinical Research Valparaiso | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949759279 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115957 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115959 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115961 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115963 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115965 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115967 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910116055 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910116057 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910116059 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116061 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116063 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116065 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116067 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116069 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116071 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116073 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116075 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116077 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116079 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116081 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116083 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116085 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116087 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116089 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116091 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116093 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116173 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 11/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116175 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 11/30/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897183441 |
| Principal investigator 1 | Novo Nordisk AS | $1,869.48 | 11/30/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897268121 |
| Principal investigator 1 | ModernaTX, Inc. | $6,000.00 | 11/23/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study | No dispute reported | 06/30/2026 | 963497211 |
| Principal investigator 1 | Mylan Specialty L.P. | $7,443.17 | 11/23/2022 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 962566599 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,792.00 | 11/21/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230067 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194765 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194767 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194769 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194771 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194773 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194775 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194777 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194779 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194781 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194975 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195227 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195229 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195231 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195233 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195235 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195237 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195239 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195241 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195243 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195543 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195545 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195547 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195549 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195551 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195553 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195555 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195557 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195559 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195561 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195563 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195565 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195567 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195569 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195571 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195895 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195897 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195899 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195901 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195903 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195905 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195907 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196103 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196281 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196283 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196285 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196287 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196289 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196291 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196293 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196295 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196297 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196299 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196301 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199555 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199557 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199559 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199561 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199563 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199565 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199567 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199569 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199751 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199753 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199755 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200005 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200007 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200009 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200011 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200013 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200015 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200017 |
| Principal investigator 1 | ModernaTX, Inc. | $2,107.98 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200019 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200021 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200023 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200025 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200331 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200333 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200335 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200337 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200339 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200341 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200343 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200345 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200347 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200349 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200351 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200657 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200659 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200661 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200663 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200665 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200667 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200669 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201011 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201013 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201015 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201017 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201019 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201021 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201377 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201379 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201831 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201833 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201835 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201837 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201839 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202165 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202167 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202169 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202171 |
| Principal investigator 1 | ModernaTX, Inc. | $2,534.49 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202173 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202175 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202177 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202179 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202547 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202549 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202551 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202553 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202555 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202557 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202559 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202561 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202563 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202913 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202915 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202917 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202919 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202921 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202923 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202925 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202927 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203083 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203085 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203087 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203089 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203091 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203583 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203585 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203587 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203589 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203591 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203593 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203595 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203597 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203599 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203601 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203603 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203605 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203931 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203933 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203935 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203937 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203939 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203941 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203943 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204237 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204239 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204241 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204243 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204245 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204247 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204547 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204549 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204551 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204553 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204555 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204557 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204559 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205009 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205011 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205013 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205015 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205017 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205019 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205021 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205295 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205297 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205299 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205301 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205303 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205305 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205307 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205309 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205597 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205599 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205601 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205779 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205781 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205783 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205785 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205787 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205789 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205791 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206063 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206065 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206067 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206069 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206071 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206073 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206075 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206077 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206079 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206081 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206083 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206313 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206315 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206317 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206319 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206321 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206323 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206325 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207139 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207143 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207147 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207151 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207155 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207159 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207163 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207167 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207171 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207175 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207491 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207495 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207499 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207503 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207507 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207511 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207515 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207519 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207523 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207527 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208493 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208497 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208501 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208505 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208509 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208513 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208517 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208521 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208523 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208527 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208531 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208535 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208539 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208543 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208547 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208853 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208855 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208859 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208863 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208867 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209195 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209199 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209201 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209205 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209209 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209213 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209217 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209649 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209651 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209653 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209655 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209657 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209659 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209661 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209663 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209665 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209667 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210025 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210027 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210029 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210031 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210033 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210035 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210037 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210039 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210353 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210355 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210357 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210359 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210361 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210363 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210365 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210605 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210607 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210609 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210611 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210613 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210987 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210989 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210991 |
| Principal investigator 1 | ModernaTX, Inc. | $2,534.49 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210993 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210995 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211229 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211231 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211233 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211235 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211237 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211239 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211241 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211689 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211691 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211693 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211695 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211697 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211699 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211701 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211703 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211705 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211707 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211709 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211711 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211713 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212041 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212043 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212045 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212047 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212049 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212051 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212053 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212055 |
| Principal investigator 1 | ModernaTX, Inc. | $2,534.49 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212351 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212353 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212355 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212357 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212359 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212361 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212363 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212365 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212367 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212369 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212371 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212683 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212685 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212687 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212689 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213073 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213075 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213077 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213079 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213081 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213083 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213085 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213087 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213089 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213091 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213093 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213407 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213409 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213411 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213413 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213415 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213417 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213419 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213895 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213897 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213899 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213901 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213903 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213905 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213907 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214213 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214215 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214217 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214219 |
| Principal investigator 1 | ModernaTX, Inc. | $2,107.98 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214221 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214223 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214225 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214227 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214229 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214465 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214467 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214469 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214471 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214473 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214475 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214663 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214665 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214667 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214669 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214671 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214673 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214675 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214677 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214893 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214895 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214897 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214899 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214901 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214903 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214905 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214907 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215461 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215467 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215473 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215479 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215483 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215489 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215495 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215501 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215507 |
| Principal investigator 1 | ModernaTX, Inc. | $2,107.98 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216283 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216285 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216287 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216289 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216291 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216293 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216295 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216771 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216773 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216775 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216777 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216779 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216781 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216783 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216785 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216787 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216789 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217047 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217049 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217051 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217053 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217055 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217057 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217549 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217551 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217553 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217555 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217557 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217559 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217561 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217563 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217927 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217929 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217931 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217933 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217935 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217937 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217939 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217941 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217943 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217945 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218283 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218285 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218287 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218289 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218291 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218293 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218295 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218457 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218459 |
| Principal investigator 1 | ModernaTX, Inc. | $2,107.98 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218461 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218463 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218465 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218805 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218807 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218809 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218811 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218813 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218815 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219143 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219145 |
| Principal investigator 1 | ModernaTX, Inc. | $753.48 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219147 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219149 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219151 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219153 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219155 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219157 |
| Principal investigator 1 | ModernaTX, Inc. | $558.18 | 11/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219159 |
| Principal investigator 1 | ModernaTX, Inc. | $106,832.00 | 11/18/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496993 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,500.00 | 11/16/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) | No dispute reported | 06/30/2026 | 914602603 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 11/16/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897225743 |
| Principal investigator 1 | ModernaTX, Inc. | $1,378.48 | 11/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203325 |
| Principal investigator 1 | PFIZER INC. | $3,969.00 | 11/10/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949779123 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,500.00 | 11/09/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO | No dispute reported | 06/30/2026 | 943949437 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 11/09/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO | No dispute reported | 06/30/2026 | 943949439 |
| Principal investigator 1 | PFIZER INC. | $1,984.50 | 11/08/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949779121 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $14,920.00 | 11/02/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116359 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115987 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115989 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910115991 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910116043 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910116045 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910116047 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910116049 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910116051 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) | No dispute reported | 06/30/2026 | 910116053 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116133 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116135 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116137 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116139 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116141 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116143 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116145 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116147 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116149 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116151 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116153 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116155 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116157 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116159 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116161 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116163 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116165 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116167 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 10/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116169 |
| Principal investigator 1 | ModernaTX, Inc. | $18,205.09 | 10/28/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496983 |
| Principal investigator 1 | PFIZER INC. | $8,300.00 | 10/28/2022 | Non-covered Recipient Entity Buynak Clinical Research | A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 949790705 |
| Principal investigator 1 | Mylan Specialty L.P. | $3,443.17 | 10/27/2022 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 962566587 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,826.00 | 10/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218329 |
| Principal investigator 1 | Janssen Research & Development, LLC | $54,856.00 | 10/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230069 |
| Principal investigator 1 | ModernaTX, Inc. | $3,621.52 | 10/26/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209823 |
| Principal investigator 1 | ModernaTX, Inc. | $56,534.80 | 10/21/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496969 |
| Principal investigator 1 | Novo Nordisk AS | $3,760.90 | 10/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896938526 |
| Principal investigator 1 | Novo Nordisk AS | $1,507.68 | 10/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897225737 |
| Recipient | Novo Nordisk AS | $50.00 | 10/19/2022 | Covered Recipient Physician | EX9536-4388 | No dispute reported | 06/30/2026 | 897216673 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $18.90 | 10/17/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116171 |
| Principal investigator 1 | ModernaTX, Inc. | $4,078.35 | 10/14/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496979 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195411 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195735 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202007 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203077 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204893 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204895 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205923 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207443 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209221 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209225 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209815 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210519 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211183 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211185 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211187 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211565 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212573 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212863 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214069 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217725 |
| Principal investigator 1 | ModernaTX, Inc. | $3,779.37 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218093 |
| Principal investigator 1 | ModernaTX, Inc. | $12.60 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218693 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $10,909.00 | 10/07/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218341 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $11,091.00 | 10/05/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) | No dispute reported | 06/30/2026 | 910116355 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 10/05/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496973 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 10/03/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200195 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 10/03/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203755 |
| Principal investigator 1 | ModernaTX, Inc. | $10,000.00 | 10/03/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210513 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115799 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115801 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115803 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115805 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115807 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115809 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115811 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115815 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115817 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115877 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115879 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115903 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115905 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115907 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115909 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115911 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115913 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115915 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115917 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115919 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115921 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115923 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115925 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115927 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115929 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115931 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115933 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115935 |
| Principal investigator 1 | ModernaTX, Inc. | $16.00 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963325537 |
| Principal investigator 1 | Novo Nordisk AS | $5,881.54 | 09/30/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854547 |
| Principal investigator 1 | Novo Nordisk AS | $2,378.16 | 09/28/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897269053 |
| Principal investigator 1 | PFIZER INC. | $37.26 | 09/28/2022 | Non-covered Recipient Entity Velocity Clinical Research Valparaiso | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949759277 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/26/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897162835 |
| Principal investigator 1 | PFIZER INC. | $15,947.00 | 09/24/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949790347 |
| Principal investigator 1 | ModernaTX, Inc. | $62,772.00 | 09/23/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496871 |
| Principal investigator 1 | PFIZER INC. | $15,250.00 | 09/22/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949790349 |
| Principal investigator 1 | ModernaTX, Inc. | $15,377.18 | 09/21/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496735 |
| Principal investigator 1 | PFIZER INC. | $18.63 | 09/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Valparaiso | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 949759275 |
| Recipient | Novo Nordisk AS | $500.00 | 09/14/2022 | Covered Recipient Physician | Not supplied | No dispute reported | 06/30/2026 | 897119891 |
| Recipient | Novo Nordisk AS | $772.49 | 09/14/2022 | Covered Recipient Physician | Not supplied | No dispute reported | 06/30/2026 | 897215221 |
| Principal investigator 1 | PFIZER INC. | $3,412.80 | 09/14/2022 | Non-covered Recipient Entity Buynak Clinical Research | A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 949790351 |
| Principal investigator 1 | ModernaTX, Inc. | $55,969.20 | 09/07/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496867 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115787 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115789 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115791 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115793 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115795 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115797 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115837 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115839 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115841 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115843 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115845 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115847 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115849 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115851 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115853 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115855 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115857 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115859 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115861 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115863 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115865 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115867 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115869 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115871 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115873 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115875 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115953 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 08/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115955 |
| Principal investigator 1 | ModernaTX, Inc. | $498.00 | 08/30/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963325531 |
| Principal investigator 1 | Mylan Specialty L.P. | $7,092.03 | 08/29/2022 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 962566291 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $34,515.00 | 08/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218103 |
| Principal investigator 1 | Janssen Research & Development, LLC | $45,540.00 | 08/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229979 |
| Principal investigator 1 | ModernaTX, Inc. | $26,008.80 | 08/26/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496861 |
| Principal investigator 1 | Novo Nordisk AS | $1,800.00 | 08/26/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896892057 |
| Principal investigator 1 | Novo Nordisk AS | $1,508.63 | 08/26/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896932601 |
| Principal investigator 1 | ModernaTX, Inc. | $9,900.90 | 08/24/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496731 |
| Principal investigator 1 | Novo Nordisk AS | $358.56 | 08/22/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897183293 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,660.00 | 08/19/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218075 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,846.00 | 08/19/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229977 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 08/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897183447 |
| Principal investigator 1 | PFIZER INC. | $5,406.80 | 08/16/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949802709 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $4,992.00 | 08/15/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218091 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 08/12/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896855867 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 08/12/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896876707 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854535 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854537 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854539 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854541 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854543 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854549 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854551 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854581 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854683 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896863447 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896863455 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896863459 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896863463 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896863495 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896863503 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896875389 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896875393 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896875397 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896875401 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896875405 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896875409 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896892049 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896892053 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896892061 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896892065 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896892069 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896892071 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896908941 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896908945 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896910073 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896910077 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896910081 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896910084 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896910087 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896910096 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896910101 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896910151 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896932443 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896932447 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896932451 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896932455 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896932459 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896932605 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896932953 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896932957 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896932961 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896938509 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896938514 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896938518 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896938521 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896939075 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942199 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942577 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942581 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942585 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942589 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942597 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942601 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942605 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942609 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942613 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896942617 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945153 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945543 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945547 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945551 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945555 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945559 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945571 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945583 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945639 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945937 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896989982 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896989987 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896989991 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896989997 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896990001 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896990053 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896992189 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896992193 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896992197 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896992201 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897009009 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897009014 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897009019 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897009021 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897009027 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897009029 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024421 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024469 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024473 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024485 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024489 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024493 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024495 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024563 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024567 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024571 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024575 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024579 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024583 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897024587 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 08/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897033777 |
| Principal investigator 1 | ModernaTX, Inc. | $17,475.75 | 08/10/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496741 |
| Principal investigator 1 | ModernaTX, Inc. | $67,478.74 | 08/10/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496745 |
| Principal investigator 1 | ModernaTX, Inc. | $133,355.60 | 08/10/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496877 |
| Principal investigator 1 | Novo Nordisk AS | $3,021.34 | 08/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896942285 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $38,444.00 | 08/05/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116343 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,826.00 | 08/03/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218095 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115819 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115821 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115823 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115825 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115827 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115829 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115831 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115833 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115835 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115881 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115883 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115885 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115887 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115889 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115891 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115893 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115895 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115897 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115899 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115901 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115937 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115939 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115941 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115943 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115945 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115947 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115949 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115951 |
| Principal investigator 1 | PFIZER INC. | $7,197.16 | 07/29/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949807411 |
| Principal investigator 1 | Novo Nordisk AS | $4,381.90 | 07/27/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896992207 |
| Principal investigator 1 | Novo Nordisk AS | $2,378.16 | 07/27/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897013428 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $28,719.00 | 07/22/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218099 |
| Principal investigator 1 | Janssen Research & Development, LLC | $117,861.00 | 07/22/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229975 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/22/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897250427 |
| Principal investigator 1 | ModernaTX, Inc. | $2,720.00 | 07/20/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496727 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $10,296.00 | 07/06/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116341 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,040.00 | 07/05/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229983 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115619 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115621 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115635 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115637 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115639 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115641 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115643 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115645 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115647 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115649 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115751 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115753 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115755 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115757 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115759 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115761 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115763 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115765 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115767 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115769 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115771 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115773 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115775 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115777 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115779 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115781 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115783 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/30/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115785 |
| Principal investigator 1 | Novo Nordisk AS | $4,995.58 | 06/29/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945567 |
| Principal investigator 1 | Novo Nordisk AS | $717.12 | 06/29/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897120555 |
| Principal investigator 1 | PFIZER INC. | $941.64 | 06/29/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949814871 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/24/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897078267 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $16,972.00 | 06/20/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217879 |
| Principal investigator 1 | Mylan Specialty L.P. | $3,823.45 | 06/20/2022 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 962565981 |
| Principal investigator 1 | Janssen Research & Development, LLC | $46,384.00 | 06/17/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229815 |
| Principal investigator 1 | Janssen Research & Development, LLC | $46,384.00 | 06/17/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229903 |
| Principal investigator 1 | Novo Nordisk AS | $52.43 | 06/16/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897132008 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,826.00 | 06/15/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217875 |
| Principal investigator 1 | PFIZER INC. | $1,883.28 | 06/15/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949814803 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,743.00 | 06/10/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217871 |
| Principal investigator 1 | ModernaTX, Inc. | $71,308.35 | 06/08/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496749 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $61,495.00 | 06/01/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116033 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,275.00 | 06/01/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217867 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,720.00 | 06/01/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229813 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,720.00 | 06/01/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229901 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/01/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897000881 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115627 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115629 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115633 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115665 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115667 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115669 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115671 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115673 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115675 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115677 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115715 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115717 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115719 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115721 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115723 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115725 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115727 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115729 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115731 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115733 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115735 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115737 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115739 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115741 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115743 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115745 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115747 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115749 |
| Principal investigator 1 | PFIZER INC. | $1,883.28 | 05/27/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949744623 |
| Principal investigator 1 | Novo Nordisk AS | $2,613.95 | 05/25/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896939071 |
| Principal investigator 1 | Novo Nordisk AS | $1,149.12 | 05/25/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897120505 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $32,970.00 | 05/20/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217863 |
| Principal investigator 1 | Janssen Research & Development, LLC | $71,541.00 | 05/20/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229811 |
| Principal investigator 1 | Janssen Research & Development, LLC | $71,541.00 | 05/20/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229899 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 05/18/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897077157 |
| Principal investigator 1 | PFIZER INC. | $2,197.16 | 05/14/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949744617 |
| Recipient | Novo Nordisk AS | $125.00 | 05/13/2022 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 896865487 |
| Recipient | Novo Nordisk AS | $291.56 | 05/12/2022 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 897021185 |
| Recipient | Novo Nordisk AS | $318.00 | 05/11/2022 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 896942989 |
| Recipient | Novo Nordisk AS | $592.74 | 05/11/2022 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 897021181 |
| Recipient | Novo Nordisk AS | $213.75 | 05/11/2022 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 897031251 |
| Recipient | Novo Nordisk AS | $92.00 | 05/11/2022 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 897031607 |
| Recipient | Novo Nordisk AS | $149.05 | 05/11/2022 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 897033345 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,480.00 | 05/04/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229809 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,480.00 | 05/04/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229897 |
| Principal investigator 1 | ModernaTX, Inc. | $10,172.40 | 05/04/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496857 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115623 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115625 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115631 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115651 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115653 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115655 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115657 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115659 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115661 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115663 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115679 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115681 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115683 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115685 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115687 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115689 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115691 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115693 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115695 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115697 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115699 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115701 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115703 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115705 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115707 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115709 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115711 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115713 |
| Principal investigator 1 | Novo Nordisk AS | $4,021.90 | 04/29/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896945563 |
| Principal investigator 1 | Novo Nordisk AS | $1,434.24 | 04/29/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897121579 |
| Principal investigator 1 | PFIZER INC. | $313.88 | 04/29/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949821015 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $22,167.00 | 04/25/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217859 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $865.00 | 04/22/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116025 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $276.00 | 04/22/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116027 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $50,000.00 | 04/22/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910116029 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $166.00 | 04/22/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116031 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $138.00 | 04/22/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116035 |
| Principal investigator 1 | Janssen Research & Development, LLC | $67,323.00 | 04/22/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229807 |
| Principal investigator 1 | Janssen Research & Development, LLC | $67,323.00 | 04/22/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229895 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $2,905.00 | 04/20/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217855 |
| Principal investigator 1 | Mylan Specialty L.P. | $7,500.00 | 04/07/2022 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 962565969 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115337 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115341 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115345 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115347 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115351 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115356 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115359 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115363 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115367 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115371 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115375 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115379 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115383 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115387 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115391 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115395 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115399 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115403 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115407 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115411 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115413 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115417 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115421 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115425 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115429 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115433 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115437 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 03/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115441 |
| Principal investigator 1 | Novo Nordisk AS | $899.10 | 03/31/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896855863 |
| Principal investigator 1 | Novo Nordisk AS | $899.10 | 03/31/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896893325 |
| Principal investigator 1 | Novo Nordisk AS | $899.10 | 03/31/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896916305 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $41,520.00 | 03/28/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217483 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,784.00 | 03/25/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229753 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,784.00 | 03/25/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230029 |
| Principal investigator 1 | ModernaTX, Inc. | $201,660.30 | 03/25/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496763 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 03/25/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496843 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 03/25/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496847 |
| Principal investigator 1 | ModernaTX, Inc. | $6,500.00 | 03/25/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 963496851 |
| Principal investigator 1 | Novo Nordisk AS | $2,702.27 | 03/25/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 896854545 |
| Principal investigator 1 | Novo Nordisk AS | $1,020.06 | 03/25/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896949263 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/25/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897077153 |
| Principal investigator 1 | Novo Nordisk AS | $1,581.12 | 03/25/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897078263 |
| Principal investigator 1 | Janssen Research & Development, LLC | $121,415.00 | 03/23/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229751 |
| Principal investigator 1 | Janssen Research & Development, LLC | $121,415.00 | 03/23/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230027 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,000.00 | 03/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116013 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 03/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116015 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $8,820.00 | 03/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116017 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,000.00 | 03/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910116019 |
| Principal investigator 1 | PFIZER INC. | $151.88 | 03/16/2022 | Non-covered Recipient Entity Buynak Clinical Research | A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 949825525 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $3,976.00 | 03/09/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217479 |
| Principal investigator 1 | PFIZER INC. | $10,524.62 | 03/03/2022 | Non-covered Recipient Entity Buynak Clinical Research | A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 949825779 |
| Principal investigator 1 | Novo Nordisk AS | $790.56 | 03/02/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897126203 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115503 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115505 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115507 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115509 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115511 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115513 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115515 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115517 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115519 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115521 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115523 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115525 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115527 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115529 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115591 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115593 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115595 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115597 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115599 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115601 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115603 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115605 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115607 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115609 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115611 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115613 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115615 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115617 |
| Principal investigator 1 | Novo Nordisk AS | $899.10 | 02/28/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896855865 |
| Principal investigator 1 | Novo Nordisk AS | $899.10 | 02/28/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896916309 |
| Principal investigator 1 | Novo Nordisk AS | $899.10 | 02/28/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896916313 |
| Principal investigator 1 | ModernaTX, Inc. | $163,520.44 | 02/25/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496759 |
| Principal investigator 1 | Novo Nordisk AS | $2,912.36 | 02/25/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896942281 |
| Principal investigator 1 | Novo Nordisk AS | $4,248.58 | 02/25/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897009038 |
| Principal investigator 1 | PFIZER INC. | $8,575.92 | 02/25/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949830723 |
| Principal investigator 1 | Janssen Research & Development, LLC | $463,482.00 | 02/18/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229749 |
| Principal investigator 1 | Janssen Research & Development, LLC | $463,482.00 | 02/18/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230025 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 02/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897132003 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $20,112.00 | 02/16/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $144,914.00 | 02/16/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229747 |
| Principal investigator 1 | Janssen Research & Development, LLC | $144,914.00 | 02/16/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230023 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 02/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897123503 |
| Principal investigator 1 | Novo Nordisk AS | $7,654.54 | 02/09/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 897009167 |
| Principal investigator 1 | Novo Nordisk AS | $4,448.38 | 02/07/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896893329 |
| Principal investigator 1 | Novo Nordisk AS | $2,810.16 | 02/07/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 896973299 |
| Principal investigator 1 | PFIZER INC. | $27,334.18 | 02/04/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949830713 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115445 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115449 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115451 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115453 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115455 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115457 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115459 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115461 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115463 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115465 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115467 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115469 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115471 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115473 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115475 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115477 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115479 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115481 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 910115483 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115485 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115487 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115489 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115491 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115493 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115495 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115497 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115499 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2022 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115501 |
| Principal investigator 1 | Novo Nordisk AS | $899.10 | 01/31/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896946857 |
| Principal investigator 1 | Novo Nordisk AS | $899.10 | 01/31/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896946861 |
| Principal investigator 1 | Novo Nordisk AS | $899.10 | 01/31/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN1436-4478 | No dispute reported | 06/30/2026 | 896946865 |
| Principal investigator 1 | PFIZER INC. | $4,255.20 | 01/28/2022 | Non-covered Recipient Entity Buynak Clinical Research | A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 949831583 |
| Principal investigator 1 | Janssen Research & Development, LLC | $133,553.00 | 01/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229745 |
| Principal investigator 1 | Janssen Research & Development, LLC | $133,553.00 | 01/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230021 |
| Principal investigator 1 | ModernaTX, Inc. | $74,228.40 | 01/26/2022 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 963496755 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $24,614.33 | 01/24/2022 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C | No dispute reported | 06/30/2026 | 909392631 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,000.00 | 01/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115995 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 01/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115997 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $8,820.00 | 01/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910115999 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,000.00 | 01/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc. | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 910116001 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $23,022.00 | 01/21/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217471 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,686.00 | 01/21/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229743 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,686.00 | 01/21/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230019 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 01/21/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 897179127 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $360.00 | 01/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Aged 50 to 84 Years | No dispute reported | 06/30/2026 | 935567681 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $6,840.00 | 01/21/2022 | Non-covered Recipient Entity Velocity Clinical Research Inc | Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Aged 50 to 84 Years | No dispute reported | 06/30/2026 | 935567693 |
| Principal investigator 1 | PFIZER INC. | $7,182.02 | 01/08/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949831581 |